Amplite® Fluorimetric DPP4 Inhibitor Screening Kit

Amplite® Fluorimetric DPP4 Inhibitor Screening Kit is a fluorimetric assay kit for screening and evaluating compounds that inhibit DPP4 activity in a microplate format.

Detection Principle: Detects DPP4 cleavage of a specific fluorogenic substrate.
Specificity: Includes sitagliptin as a reference DPP4 inhibitor.
Workflow: Optimized for high-throughput inhibitor screening.
Instrument Compatibility: Fluorescence detection at Ex/Em 360/460 nm.

Sitagliptin dose response was measured with the Amplite® Fluorimetric DPP4 Inhibitor Screening Kit on a 96-well black microplate after incubation for 30 minutes at room temperature. The fluorescence intensity was monitored using a Gemini fluorescence microplate reader (Molecular Devices) Ex/Em = 360/460 nm, Cutoff = 435 nm.

Protocol

SDS

COA

Catalog	Size	Price	Quantity
11324	100 Tests	Price

Overview

The Amplite® Fluorimetric DPP4 Inhibitor Screening Kit provides an efficient and direct method for evaluating potential DPP4 inhibitors. DPP4 activity is quantified by the enzymatic cleavage of a specific substrate, resulting in a fluorescent product (Ex/Em = 360/460 nm), which correlates directly with the enzymatic activity present. This kit includes Sitagliptin, a well-characterized DPP4 inhibitor used in diabetes treatment, as a reference control, facilitating the assessment of inhibitor efficacy. The assay is optimized for high-throughput screening applications. Dipeptidyl peptidase-4 (DPP4), also referred to as CD26, ADCP2, or DPP, is a transmembrane glycoprotein within the prolyl oligopeptidase family. DPP4 functions as a serine exopeptidase, cleaving N-terminal X-proline and X-alanine residues from polypeptides. It is implicated in numerous physiological processes, including glucose metabolism via regulation of glucagon-like peptide-1 (GLP-1), immune modulation through its role as a receptor on various immune cells, signal transduction as a transmembrane protein responsive to growth factors and chemokines, and tumor suppression via immune system interactions. Thus, DPP4 inhibitors are critical in the therapeutic management of type-2 diabetes.

References

View all 50 references: Citation Explorer

Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors.

Authors:

Suzuki, Yuta and Kaneko, Hidehiro and Okada, Akira and Komuro, Jin and Fujiu, Katsuhito and Takeda, Norifumi and Morita, Hiroyuki and Ako, Junya and Nishiyama, Akira and Yano, Yuichiro and Ieda, Masaki and Node, Koichi and Yasunaga, Hideo and Komuro, Issei

Journal:

Hypertension research : official journal of the Japanese Society of Hypertension (2024)

Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study.

Authors:

Ueda, Peter and Wintzell, Viktor and Melbye, Mads and Eliasson, Björn and Söderling, Jonas and Gudbjörnsdottir, Soffia and Hveem, Kristian and Jonasson, Christian and Svanström, Henrik and Hviid, Anders and Pasternak, Björn

Journal:

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Associatio (2024): 1226-1237.e14

Esophageal involvement in DPP4 inhibitor-associated bullous pemphigoid.

Authors:

Brufau-Cochs, Magí and Alamon-Reig, Francesc and Luque-Luna, Mar and Bosch-Amate, Xavier and Moreta, Maria José and Bassegoda, Octavi and Mascaró, José M

Journal:

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (2024): 430-432

Low dose sulphonylurea plus DPP4 inhibitor lower blood glucose and enhance beta cell function without hypoglycaemia.

Authors:

Cordiner, Ruth Lorna Mary and Bedair, Khaled and Mari, Andrea and Pearson, Ewan

Journal:

The Journal of clinical endocrinology and metabolism (2024)

Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus.

Authors:

Suzuki, Y and Kaneko, H and Okada, A and Ohno, R and Yokota, I and Fujiu, K and Jo, T and Takeda, N and Morita, H and Node, K and Yasunaga, H and Komuro, I

Journal:

Journal of endocrinological investigation (2024): 1261-1270

Usage and storage

Intended use

Research Use Only (RUO)

Instrument settings

Fluorescence microplate reader
Excitation	360 nm
Emission	460 nm
Cutoff	435 nm
Recommended plate	Solid black or black plate with clear bottom

Telephone
Fax
Email	sales@aatbio.com
International	See distributors
Bulk request	Inquire
Custom size	Inquire
Technical support	Contact us
Request quotation	Request
Purchase order	Send to sales@aatbio.com
Shipping	Standard overnight for United States, inquire for international

Page updated on October 26, 2026

Component A: DPP4 Assay Buffer	25 mL
Component B: DPP4 Substrate	0.35 mL
Component C: DPP4 Enzyme	20 µL
Component D: DPP4 Inhibitor (Sitagliptin)	50 µL